查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1308753

到 2030 年神经修復和再生市场预测 - 按产品、按手术、按应用、按最终用户、按地区进行全球分析

Nerve Repair and Regeneration Market Forecasts to 2030 - Global Analysis By Product, Surgery, Application, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 175+ Pages | 商品交期: 2-3个工作天内

价格

根据 Stratistics MRC 的复合年增长率为 14.1%，全球神经修復和再生市场预计 2023 年将达到 89.4 亿美元，2030 年将达到 225.2 亿美元。

可用于神经修復和再生的产品包括神经刺激器、神经调节器和生物材料装置。 这些设备用于治疗创伤性和神经退行性疾病，如阿尔茨海默病、帕金森病、肌萎缩侧索硬化症、多发性硬化症和多系统萎缩症。 由于大脑、脊髓和周围神经脆弱且容易受损，因此它们与肌肉和器官沟通的能力可能会受到损害。 这些损伤可以通过神经修復和再生产品来修復。

据 2021 年 7 月出版的《柳叶刀全球健康》杂誌报导，约有 5000 万人患有癫痫症。 据该杂誌报导，印度约有 10-1200 万人被诊断患有癫痫症。

市场动态：

驱动程序

世界发展中国家

印度、中国和巴西等新兴国家可能在预测期内为市场进入者提供显着的增长前景。 庞大的人口基数，尤其是印度和中国的人口基数，预计将成为进入该市场的公司的主要吸引力。 这是由于阿尔茨海默病、帕金森病和癫痫等神经系统疾病的患病率不断增加所致。 据世界银行称，这些国家的医疗保健支出正在增加，支持医院和门诊手术设施的增加。 由于医院和门诊手术设施是神经修復和再生产品的主要最终消费者，这被认为是市场扩张的良好指标。

限制

临床结果不确定

儘管神经病理生理学和实验表明有希望的神经治疗方式取得了重大进展，但周围神经撕脱、挤压和爆炸伤病例的临床结果仍然难以捉摸。这仍然很困难。 儘管神经损伤后积极的康復可能会减少神经损伤和创伤后肌肉废用性萎缩的发生率，但肌肉靶向去神经萎缩是神经再生努力的严重障碍。 即使神经再生效果最好，由于缺乏可行的神经肌肉接头 (NMJ) 和肌肉靶标，功能结果也很差。

机会

人口老龄化

世界发达地区的老年人口正在增加。 中风、神经病、阿尔茨海默病和帕金森病等神经系统疾病在老年人群中更为普遍。 老年人口由于其高易感性而占患者总数的很大一部分。 因此，该群体不断增长的人口将确保对神经修復和再生用于治疗神经系统疾病的持续增长的需求。

威胁

神经刺激器和神经调节器很昂贵。

使用神经调节剂的初始成本很大。 由于这些设备成本高昂，即使在负担得起的地区，它们也可能被不公平地使用。 儘管神经刺激对患者和保险公司来说初始成本很高，但对治疗的长期担忧给国家医疗保健系统带来了较小的成本。 此外，保险公司承保部分治疗，但不是全部。 这会影响医院的整体预算。 因此，这一因素很可能对市场产生相当大的影响。

COVID-19 的影响：

COVID-19疫情对神经修復和再生市场产生了不利影响。 这是因为世界各国政府实施的社会疏远措施严重限制了医院和医疗服务。 此外，COVID-19 疫情严重影响了全球医院对非 COVID-19 患者的综合护理能力。 由于许多医院和诊所仍然关闭，神经修復和重建手术的需求正在下降。

干细胞治疗细分市场将在预测期内规模最大：

由于神经系统疾病发生频率的增加、对有效治疗的需求不断增长、政府的各种举措以及生物材料研究的批准，预计干细胞治疗领域将在预测期内占据最大份额。 此外，干细胞可通过替换分化后有缺陷、死亡或垂死的脑细胞来治疗神经退行性疾病。

预计酒店业在预测期内的复合年增长率最高：

酒店业在预测期内的复合年增长率最高。 神经系统疾病发病率的上升、发展中国家医院数量的增加、神经流行病学的增长和发展都是医院领域崛起的重要驱动力。 然而，持续监测是通过提供有关患者生理状态的更多信息来帮助医疗和护理人员的好方法。 这被认为是市场增长的有利指标，因为酒店业是神经修復和再生产品的主要最终用户。

份额最大的地区：

在预测期内，神经退行性和神经发育疾病、中风和创伤性脑损伤的患病率不断上升，先进医疗基础设施的采用不断增加，以及患者对神经修復和再生方法的认识不断提高，将导致北美主导的神经修復和再生市场份额。 此外，该领域大型竞争对手的存在和频繁的产品开发也有望在市场增长中发挥重要作用。

复合年增长率最高的地区：

由于患者意识的提高、政府的支持措施、未满足的医疗需求的普遍存在以及新技术的出现，预计亚太地区在整个预测期内将呈现最高的复合年增长率。 该地区国家的经济增长、神经系统疾病发病率的上升、生活水平的提高、对优质医疗保健的需求不断增加以及医疗保健支出的增加将在整个预测期内推动该地区的市场。 此外，中国、印度、日本、澳大利亚和新加坡也对该地区的增长做出了重大贡献。

主要进展：

2022 年 10 月，Phageneis 的 Phagenyx 神经刺激系统获得美国 FDA 新批准，该系统使用电咽刺激来恢復中风后严重吞嚥困难患者的吞嚥控制。

2022 年 8 月，雅培的采用 FlexBurst 疗法的 ProClaim plus 脊髓刺激系统获得美国 FDA 批准。 FlexBurst 360 疗法是 Abbott 专有的下一代 BurstDR 刺激疗法，可覆盖躯干和四肢的六个区域的疼痛。

报告内容

  • 区域和国家级市场份额评估
  • 给新进入者的战略建议
  • 涵盖 2021 年、2022 年、2023 年、2026 年和 2030 年的市场数据
  • 市场趋势（驱动因素、干扰因素、机遇、威胁、挑战、投资机会、建议）
  • 根据市场预测提出关键业务领域的战略建议
  • 绘製主要总体趋势的竞争格局
  • 公司简介，包括详细的战略、财务状况和最新发展
  • 供应链趋势映射最新技术趋势

免费定制服务：

订阅此报告的客户将获得以下免费自定义选项之一：

  • 公司简介
    • 对其他市场参与者（最多 3 家公司）进行全面分析
    • 主要公司的SWOT分析（最多3家公司）
  • 区域细分
    • 根据客户兴趣对主要国家/地区的市场估计/预测/复合年增长率（注：基于可行性检查）
  • 竞争基准测试
    • 根据产品组合、地域分布和战略联盟对主要参与者进行基准测试

内容

第 1 章执行摘要

第二章前言

  • 执行摘要
  • 利益相关者
  • 调查范围
  • 调查方法
    • 数据挖掘
    • 数据分析
    • 数据验证
    • 研究方法
  • 调查来源
    • 主要研究来源
    • 二手研究来源
    • 先决条件

第三章市场趋势分析

  • 驱动程序
  • 制约因素
  • 机会
  • 威胁
  • 产品分析
  • 应用分析
  • 最终用户分析
  • 新兴市场
  • 新冠肺炎 (COVID-19) 的影响

第 4 章波特五力分析

  • 供应商的议价能力
  • 买家的议价能力
  • 替代品的威胁
  • 新进入者的威胁
  • 竞争公司之间存在敌对关係

第五章全球神经修復和再生市场：按产品

  • 生物材料
    • 神经包裹
    • 神经连接器
    • 神经保护器
    • 神经导管
  • 神经刺激和神经调节剂
    • 内神经刺激器
      • □神经刺激 (SNS)
      • 深部脑刺激 (DBS)
      • 迷走神经刺激 (VNS)
      • 脊髓刺激 (SCS)
      • 胃电刺激 (GES)
    • 外部神经刺激器
      • 电呼吸刺激 (RES) 设备
      • 经颅磁刺激 (TMS) 装置
      • 经皮神经电刺激 (TENS) 装置
  • 其他产品

第 6 章：神经修復和再生的全球市场：通过手术

  • 神经调节手术
  • 干细胞疗法
  • 神经移植
  • 直接神经病变

第 7 章：全球神经修復和再生市场：按应用分类

  • 神经移植
    • 异种移植
    • 自体移植物
    • 同种异体移植物
  • 神经刺激和神经调节手术
    • 内神经刺激和神经调节手术
    • 体外神经刺激和神经调节手术
  • 干细胞疗法
  • 直接神经修復/神经切除术
    • 团体筋膜修復
    • 硬膜外修復术
    • 神经周围修復
  • 用于神经修復和再生的生物材料
    • 直接神经修復/神经切除术
      • 团体筋膜修復
      • 神经周围修復
      • 硬膜外修復术
  • 其他用途

第 8 章：全球神经修復和再生市场：按最终用户划分

  • 门诊手术中心
  • 诊所
  • 医院
  • 其他最终用户

第 9 章：全球神经修復和再生市场：按地区

  • 北美
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 意大利
    • 法国
    • 西班牙
    • 欧洲其他地区
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳大利亚
    • 新西兰
    • 韩国
    • 亚太地区其他地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地区
  • 中东和非洲
    • 沙特阿拉伯
    • 阿拉伯联合酋长国
    • 卡塔尔
    • 南非
    • 其他中东和非洲地区

第 10 章主要进展

  • 合同、合作伙伴关係、联盟和合资企业
  • 收购与合併
  • 推出新产品
  • 业务扩展
  • 其他关键策略

第 11 章公司简介

  • Polyganics
  • Nevro Corp.
  • Soterix Medical, Inc.
  • Kerimedical
  • Livanova, Plc.
  • Integra Lifesciences
  • Collagen Matrix, Inc.
  • Axogen, Inc.
  • Neuropace, Inc.
  • Aleva Neurotherapeutics
  • Boston Scientific Corporation
  • Baxter International, Inc.
  • Synapse Biomedical, Inc.
  • Medtronic, Plc.
  • Abbott Laboratories
Product Code: SMRC23453

According to Stratistics MRC, the Global Nerve Repair and Regeneration Market is accounted for $8.94 billion in 2023 and is expected to reach $22.52 billion by 2030 growing at a CAGR of 14.1% during the forecast period. Neurostimulation, neuromodulators, and biomaterial devices are among the products available for nerve repair and regeneration. These devices are used to treat traumatic or neurodegenerative diseases such as Alzheimer's, Parkinson's, amyotrophic lateral sclerosis, multiple sclerosis, and multiple system atrophy. Because the brain, spinal cord, and peripheral nerves are delicate and readily damaged, they can impair the brain's capacity to communicate with muscles and organs. These damages are repaired by nerve repair and regeneration products.

According to the journal The Lancet Global Health published in July 2021, it was reported that around 50 million people suffer from epilepsy, globally. As per the same source, it was also reported that around 10-12 million people are diagnosed with epilepsy, in India.

Market Dynamics:

Driver:

Globally developing nations

Developing countries such as India, China, and Brazil are likely to provide market participants with substantial growth prospects over the projection period. The massive population base, particularly in India and China, is projected to be a big draw for enterprises approaching this market. This is aided by the increasing prevalence of neurological illnesses such as Alzheimer's, Parkinson's, and epilepsy. According to the World Bank, healthcare expenditure in these nations is increasing, which is supporting the rise of hospitals and ambulatory surgery facilities. As hospitals and ambulatory surgery centers are key end consumers of nerve repair and regeneration products, this is considered a good indicator for market expansion.

Restraint:

Uncertain clinical outcomes

Despite significant advances in neuropathophysiology and experimental indications of promising neurotherapies, obtaining clinical outcomes in cases of avulsion, crush, or blast injuries to peripheral nerves remains difficult. Although vigorous rehabilitation after a nerve injury may reduce the incidence of muscular disuse atrophy after a nerve transaction or trauma, denervation atrophy of muscle targets is a serious impediment to nerve regeneration initiatives. Even the best neuroregeneration outcomes can be harmed by the absence of a viable neuromuscular junction (NMJ) or muscle target, resulting in poor functional outcomes.

Opportunity:

Growth of geriatric population

The world's developed regions have witnessed a growth in the geriatric population. Neurologic illnesses such as stroke, neuropathy, Alzheimer's disease, and Parkinson's disease are more prevalent among the elderly population. Geriatrics make up a significant portion of the entire patient pool due to their higher susceptibility. As a result, the sustained and increased need for nerve repair and regeneration for the treatment of neurological illnesses will be ensured by the rise of this segment of the population.

Threat:

Neurostimulation and neuromodulation devices are expensive

The use of neuromodulation devices has a substantial upfront cost. Because of the high cost of these devices, they may be used disproportionately in geographical locations with varying levels of financial resources. While neurostimulation has a high up-front cost for patients and insurance companies, the costs to the nation's healthcare system from long-term concerns with the treatment are insignificant. Furthermore, insurance companies cover some but not all therapy. This has an impact on the hospital's overall budget. As a result, this element would have a considerable impact on the market.

COVID-19 Impact:

The COVID-19 epidemic had a detrimental influence on the nerve repair and regeneration market because hospital and healthcare services were drastically limited due to social distancing measures implemented by governments worldwide. Furthermore, the COVID-19 pandemic had a significant impact on the functioning of general hospital treatment for non-COVID-19 patients in hospitals around the world. The need for nerve repair and regeneration procedures is decreasing as many hospitals and clinics remain closed due to the lockdown.

The stem cell therapy segment is expected to be the largest during the forecast period:

Because of the increasing frequency of neurological illnesses as well as the growing desire for effective treatment alternatives, different government efforts, and approvals to perform research investigations of biomaterials, the Stem Cell Therapy segment is poised to hold the largest share throughout the projection period. Additionally, following differentiation, stem cells could be used to treat neurodegenerative illnesses by replacing defective, dead, or dying brain cells.

The hospitals segment is expected to have the highest CAGR during the forecast period:

The hospital segment commanded the highest CAGR throughout the projected period. The rising frequency of neurological illnesses, the increasing number of hospitals in developing countries, and the growth and development of neuroepidemiology have all been important driving factors in the hospital segment's rise. However, continuous monitoring is an outstanding approach that assists medical and nursing staff by providing more information about the patient's physiologic condition. As hospitals are the primary end-users of nerve repair and regeneration products, this is considered a favorable indicator for market growth.

Region with largest share:

During the forecast period, North America dominated the nerve repair and regeneration market share, owing to an increase in the prevalence of neurodegenerative and neurodevelopmental diseases, stroke, and traumatic brain injuries; an increase in the adoption of advanced healthcare infrastructure; and an increase in patient awareness of nerve repair and regeneration modalities. Furthermore, the presence of significant market competitors and frequent product developments in this area are projected to play an important role in market growth.

Region with highest CAGR:

Due to increased patient awareness, supportive government initiatives, the prevalence of unmet medical requirements, and the emergence of novel technologies, Asia-Pacific is expected to have the highest CAGR throughout the forecast period. Economic growth in this region's countries, the rising frequency of neurologic illnesses, the rising standard of living, the rising demand for outstanding medical care, and rising healthcare spending will drive the region's market throughout the projection period. Moreover, China, India, Japan, Australia, and Singapore are the primary contributors to the region's growth.

Key players in the market

Some of the key players in Nerve Repair and Regeneration market include Polyganics , Nevro Corp., Soterix Medical, Inc., Kerimedical, Livanova, Plc., Integra Lifesciences, Collagen Matrix, Inc., Axogen, Inc., Neuropace, Inc., Aleva Neurotherapeutics, Boston Scientific Corporation, Baxter International, Inc., Synapse Biomedical, Inc., Medtronic, Plc. and Abbott Laboratories.

Key Developments:

In October 2022, Phageneis received United States FDA de novo approval for the Phagenyx neurostimulation system, which uses pharyngeal electrical stimulation to restore swallowing control in patients with severe dysphagia post-stroke.

In August 2022, Abbott received United States FDA approval for the ProClaim plus spinal cord stimulation system featuring FlexBurst therapy. The next generation of Abbott's proprietary BurstDR stimulation, FlexBurst 360 therapy, offers pain coverage across six areas of the trunk and limbs.

Products Covered:

  • Biomaterials
  • Neurostimulation and Neuromodulation Devices
  • Other Products

Surgeries Covered:

  • Neuromodulation Surgery
  • Stem Cell Therapy
  • Nerve Grafting
  • Direct Neuropathy

Applications Covered:

  • Nerve Grafting
  • Neurostimulation and Neuromodulation Surgeries
  • Stem Cell Therapy
  • Direct Nerve Repair/Neurorrhaphy
  • Nerve Repair & Regeneration Biomaterials
  • Other Applications

End Users Covered:

  • Ambulatory Surgery Centers
  • Clinics
  • Hospitals
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Product Analysis
  • 3.7 Application Analysis
  • 3.8 End User Analysis
  • 3.9 Emerging Markets
  • 3.10 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Nerve Repair and Regeneration Market, By Product

  • 5.1 Introduction
  • 5.2 Biomaterials
    • 5.2.1 Nerve Wraps
    • 5.2.2 Nerve Connectors
    • 5.2.3 Nerve Protectors
    • 5.2.4 Nerve Conduits
  • 5.3 Neurostimulation and Neuromodulation Devices
    • 5.3.1 Internal Neurostimulation Devices
      • 5.3.1.1 Sacral Nerve Stimulation (SNS)
      • 5.3.1.2 Deep Brain Stimulation (DBS)
      • 5.3.1.3 Vagus Nerve Stimulation (VNS)
      • 5.3.1.4 Spinal Cord Stimulation (SCS)
      • 5.3.1.5 Gastric Electrical Stimulation (GES)
    • 5.3.2 External Neurostimulation Devices
      • 5.3.2.1 Respiratory Electric Stimulation (RES) Devices
      • 5.3.2.2 Transcranial Magnetic Stimulation (TMS) Devices
      • 5.3.2.3 Transcutaneous Electrical Nerve Stimulation (TENS) Devices
  • 5.4 Other Products

6 Global Nerve Repair and Regeneration Market, By Surgery

  • 6.1 Introduction
  • 6.2 Neuromodulation Surgery
  • 6.3 Stem Cell Therapy
  • 6.4 Nerve Grafting
  • 6.5 Direct Neuropathy

7 Global Nerve Repair and Regeneration Market, By Application

  • 7.1 Introduction
  • 7.2 Nerve Grafting
    • 7.2.1 Xenografts
    • 7.2.2 Autografts
    • 7.2.3 Allografts
  • 7.3 Neurostimulation and Neuromodulation Surgeries
    • 7.3.1 Internal Neurostimulation and Neuromodulation Surgeries
    • 7.3.2 External Neurostimulation and Neuromodulation Surgeries
  • 7.4 Stem Cell Therapy
  • 7.5 Direct Nerve Repair/Neurorrhaphy
    • 7.5.1 Group Fascicular Repair
    • 7.5.2 Epineural Repair
    • 7.5.3 Perineural Repair
  • 7.6 Nerve Repair & Regeneration Biomaterials
    • 7.6.1 Direct Nerve Repair/Neurorrhaphy
      • 7.6.1.1 Group Fascicular Repair
      • 7.6.1.2 Perineural Repair
      • 7.6.1.3 Epineural Repair
  • 7.7 Other Applications

8 Global Nerve Repair and Regeneration Market, By End User

  • 8.1 Introduction
  • 8.2 Ambulatory Surgery Centers
  • 8.3 Clinics
  • 8.4 Hospitals
  • 8.5 Other End Users

9 Global Nerve Repair and Regeneration Market, By Geography

  • 9.1 Introduction
  • 9.2 North America
    • 9.2.1 US
    • 9.2.2 Canada
    • 9.2.3 Mexico
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 Italy
    • 9.3.4 France
    • 9.3.5 Spain
    • 9.3.6 Rest of Europe
  • 9.4 Asia Pacific
    • 9.4.1 Japan
    • 9.4.2 China
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 New Zealand
    • 9.4.6 South Korea
    • 9.4.7 Rest of Asia Pacific
  • 9.5 South America
    • 9.5.1 Argentina
    • 9.5.2 Brazil
    • 9.5.3 Chile
    • 9.5.4 Rest of South America
  • 9.6 Middle East & Africa
    • 9.6.1 Saudi Arabia
    • 9.6.2 UAE
    • 9.6.3 Qatar
    • 9.6.4 South Africa
    • 9.6.5 Rest of Middle East & Africa

10 Key Developments

  • 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 10.2 Acquisitions & Mergers
  • 10.3 New Product Launch
  • 10.4 Expansions
  • 10.5 Other Key Strategies

11 Company Profiling

  • 11.1 Polyganics
  • 11.2 Nevro Corp.
  • 11.3 Soterix Medical, Inc.
  • 11.4 Kerimedical
  • 11.5 Livanova, Plc.
  • 11.6 Integra Lifesciences
  • 11.7 Collagen Matrix, Inc.
  • 11.8 Axogen, Inc.
  • 11.9 Neuropace, Inc.
  • 11.10 Aleva Neurotherapeutics
  • 11.11 Boston Scientific Corporation
  • 11.12 Baxter International, Inc.
  • 11.13 Synapse Biomedical, Inc.
  • 11.14 Medtronic, Plc.
  • 11.15 Abbott Laboratories

List of Tables

  • Table 1 Global Nerve Repair and Regeneration Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Nerve Repair and Regeneration Market Outlook, By Product (2021-2030) ($MN)
  • Table 3 Global Nerve Repair and Regeneration Market Outlook, By Biomaterials (2021-2030) ($MN)
  • Table 4 Global Nerve Repair and Regeneration Market Outlook, By Nerve Wraps (2021-2030) ($MN)
  • Table 5 Global Nerve Repair and Regeneration Market Outlook, By Nerve Connectors (2021-2030) ($MN)
  • Table 6 Global Nerve Repair and Regeneration Market Outlook, By Nerve Protectors (2021-2030) ($MN)
  • Table 7 Global Nerve Repair and Regeneration Market Outlook, By Nerve Conduits (2021-2030) ($MN)
  • Table 8 Global Nerve Repair and Regeneration Market Outlook, By Neurostimulation and Neuromodulation Devices (2021-2030) ($MN)
  • Table 9 Global Nerve Repair and Regeneration Market Outlook, By Internal Neurostimulation Devices (2021-2030) ($MN)
  • Table 10 Global Nerve Repair and Regeneration Market Outlook, By External Neurostimulation Devices (2021-2030) ($MN)
  • Table 11 Global Nerve Repair and Regeneration Market Outlook, By Other Products (2021-2030) ($MN)
  • Table 12 Global Nerve Repair and Regeneration Market Outlook, By Surgery (2021-2030) ($MN)
  • Table 13 Global Nerve Repair and Regeneration Market Outlook, By Neuromodulation Surgery (2021-2030) ($MN)
  • Table 14 Global Nerve Repair and Regeneration Market Outlook, By Stem Cell Therapy (2021-2030) ($MN)
  • Table 15 Global Nerve Repair and Regeneration Market Outlook, By Nerve Grafting (2021-2030) ($MN)
  • Table 16 Global Nerve Repair and Regeneration Market Outlook, By Direct Neuropathy (2021-2030) ($MN)
  • Table 17 Global Nerve Repair and Regeneration Market Outlook, By Application (2021-2030) ($MN)
  • Table 18 Global Nerve Repair and Regeneration Market Outlook, By Nerve Grafting (2021-2030) ($MN)
  • Table 19 Global Nerve Repair and Regeneration Market Outlook, By Xenografts (2021-2030) ($MN)
  • Table 20 Global Nerve Repair and Regeneration Market Outlook, By Autografts (2021-2030) ($MN)
  • Table 21 Global Nerve Repair and Regeneration Market Outlook, By Allografts (2021-2030) ($MN)
  • Table 22 Global Nerve Repair and Regeneration Market Outlook, By Neurostimulation and Neuromodulation Surgeries (2021-2030) ($MN)
  • Table 23 Global Nerve Repair and Regeneration Market Outlook, By Internal Neurostimulation and Neuromodulation Surgeries (2021-2030) ($MN)
  • Table 24 Global Nerve Repair and Regeneration Market Outlook, By External Neurostimulation and Neuromodulation Surgeries (2021-2030) ($MN)
  • Table 25 Global Nerve Repair and Regeneration Market Outlook, By Stem Cell Therapy (2021-2030) ($MN)
  • Table 26 Global Nerve Repair and Regeneration Market Outlook, By Direct Nerve Repair/Neurorrhaphy (2021-2030) ($MN)
  • Table 27 Global Nerve Repair and Regeneration Market Outlook, By Group Fascicular Repair (2021-2030) ($MN)
  • Table 28 Global Nerve Repair and Regeneration Market Outlook, By Epineural Repair (2021-2030) ($MN)
  • Table 29 Global Nerve Repair and Regeneration Market Outlook, By Perineural Repair (2021-2030) ($MN)
  • Table 30 Global Nerve Repair and Regeneration Market Outlook, By Nerve Repair & Regeneration Biomaterials (2021-2030) ($MN)
  • Table 31 Global Nerve Repair and Regeneration Market Outlook, By Direct Nerve Repair/Neurorrhaphy (2021-2030) ($MN)
  • Table 32 Global Nerve Repair and Regeneration Market Outlook, By Other Applications (2021-2030) ($MN)
  • Table 33 Global Nerve Repair and Regeneration Market Outlook, By End User (2021-2030) ($MN)
  • Table 34 Global Nerve Repair and Regeneration Market Outlook, By Ambulatory Surgery Centers (2021-2030) ($MN)
  • Table 35 Global Nerve Repair and Regeneration Market Outlook, By Clinics (2021-2030) ($MN)
  • Table 36 Global Nerve Repair and Regeneration Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 37 Global Nerve Repair and Regeneration Market Outlook, By Other End Users (2021-2030) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.